EP Vantage Pharma, Biotech & Medtech 2017 in Review

Fast pace of drug and device approvals in 2017 signals wider sector health for biopharma

Drug makers entered 2017 fearing the worst about retaining their US pricing power. They exited the year more jubilant, since on most measures, 2017 delivered a resurgence for pharma and biotech. The picture was similar for the medical technology industry, though life got tougher for the smaller groups.

Our report offers analysis and expert commentary on M&A deals, venture financing, initial public offerings and FDA approvals in the pharma and medtech sectors during 2017.

Key Highlights

  • All major healthcare indices climbed in 2017, echoing wider stock market strength

  • The $80bn spent on pharma & biotech acquisitions in 2017 makes it the slowest M&A year of the past five

  • With two record-breaking final quarters under its belt 2017 was a huge year for biotech venture funding

  • In medtech, the total value of all mergers closed in 2017 came in just shy of $100bn

Download Your Copy